CONCLUSIONS	The clinical trial ( EORTC protocol ALL n [ symbol : see text ] 5881 ) , comparing the oral and i.v. administrations of mercaptopurine , will demonstrate if the i.v. administration reduces the incidence of CNS relapses .\